medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2009, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2009; 7 (4)

Pemphigus foliaceus. A case report

Gatica TM, Garza GR, Salas AJC

Language: Spanish
References: 38
Page: 265-269
PDF size: 222.28 Kb.


ABSTRACT

Pemphigus foliaceus is an autoimmune chronic bullous disorder of the skin characterized by intraepidermal blisters in the upper part of epidermis due to acantholysis, and characterized by flaccid bullae, scales crusting and erosions. The disease is caused by pathogenic IgG autoantibodies directed against Tesmoglein 1 (a desmosome protein located on the surface of keratinocytes). The diagnosis is based on the clinical and histopathological findings, Tzanck test, direct and indirect inmmunofluorescence and serology (ELISA). Nowadays we have good options of treatment for this disease, but we still lack better guidelines. We report a 50 year-old male patient with pemphigus foliaceus .


REFERENCES

  1. Edelson RL. “Pemphigus - decoding the cellular language of cutaneous autoimmunity”. N Engl J Med 2000; 343(1): 60-61.

  2. Baroni A. “Vesicular and Bullous Disorders: Pemphigus”. Dermatol Clin 2007; 25(4): 597-603.

  3. Stanley JR., Amagai M. “Pemphigus, Bullous Impetigo, and the Staphy lococcal Scalded-Skin Syndrome”. N Engl J Med 2006; 355(17): 1800-1810

  4. Chorzelski TP., Hashimoto T., Amagai M., Sysa-Jedrzejowska A., Choczaj A., Nousari HC., et al. “Paraneoplastic pemphigus with cutaneous and serological features of pemphigus foliaceus”. Br J Dermatol 1999; 141(2): 357-359.

  5. Schwartz R. “Pemphigus Foliaceus” En: eMedicine: Dermatology serial online 2009 May cited 2009 Jul 29. Disponible en: http://emedicine. medscape.com/article/1064019-overview

  6. Ahmed, A. et al. “Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris”. Proc Natl Acad Sci 1990; 87(19): 7658-7662.

  7. Davidson A., “Diamond B. Autoimmune Diseases”. N Engl J Med 2001; 345(5): 340-350.

  8. Kanwar AJ. “Pemphigus in children”. Int J Dermatol 1991; 30(5): 343-346.

  9. Brenner, S. Sasson A., Sharon O. “Pemphigus and infections”. Clin in Dermatol 2002; 20(2): 114-118.

  10. Amagai M. “Adhesion molecules. I: Keratinocyte-Keratinocyte interactions. Cadherins and pemphigus”. J Invest Dermatol 1995; 104(1): 146-152.

  11. Cozzani, E. Cacciapuoti, M. Paroidi, A. Ghohestani, R. “Desmosomes and their autoimmune pathologies”. Eur Jof Dermatology 2000; 10(4): 255-261.

  12. Nguyen VT., Arredondo J., Chernyavsky AI., Kitajima Y., Grando SA. “Keratinocyte acetylcholine receptors regulate cell adhesion”. Life Sci 2003; 72(18): 2081-2085.

  13. Amagai M. “Desmoglein as a target in autoimmunity and infection”. J Am Acad Dermatol 2003; 48(2): 244-252.

  14. Uzun S., Durdu M. “The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus”. J Am Acad Dermatol 2006; 54(3): 411-415.

  15. Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K. “Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1”. J Invest Dermatol 1998; 110(1): 76-78.

  16. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. “Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris”. J Clin Invest 1999; 103(4): 461-468.

  17. Hernanz, J. “Patología mucocutánea ampollosa”. Medicine 2002; 8(90): 4860-4866.

  18. Pfutze M, Niedermeier A, Hertl M, et al. “Introducing a novel Auto - immune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus”. Eur J Dermatol 2007; 17(1): 4-11.

  19. Mutasim, D. “Management of autoimmune bullous diseases: Pharma - cology and therapeutics”. J Am Acad Dermatol 2004; 51(6): 859-877.

  20. Cianchini, G., Corona, R., Frezzolini, A., Ruffelli, M., Didona, B., Puddu, P. “Treatment of Severe Pemphigus With Rituximab: Report of 12 Cases and a Review of the Literature”. Arch Dermatol 2007; 143(8): 1033-1038.

  21. Dupuy A., Viguier M., Bedane C., Cordoliani F., Blaise S., Aucouturier F., et al. “Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)”. Arch Dermatol 2004; 140(1): 91-96.

  22. Gubinelli E. “Pemphigus foliaceus treated with etanercept”. J Am Acad Dermatol 2006; 55(6): 1107-1108.

  23. Amagai M., Ikeda S., Shimizu H., Iizuka H., Hanada K., Aiba S., et al. “A randomized double-blind trial of intravenous immunoglobulin for pemphigus”. J Am Acad Dermatol 2009; 60(4): 595-603.

  24. Lüftl M., Stauber A., Mainka A., Klingel R., Schuler G., Hertl M., et al. “Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber”. Br J Dermatol 2003; 149(3): 598-605.

  25. Bastian BC., Nuss B., Romisch J., Krauz M., Brocker EB. “Auto - antibodies to annexins: a diagnostic marker for cutaneous disorders?”. J Dermatol Sci 1994; 8(3): 194-202.

  26. Grando SA. “New approaches to the treatment of pemphigus”. J Investig Dermatol Symp Proc 2004; 9(1): 84-91.

  27. Ruocco E., Aurilia A., Ruocco V. “Precautions and suggestions for pemphigus patients”. Dermatology 2001; 203(3): 201-207.

  28. Martin LK, Agero AL, Werth V, Villanueva E, Segall J, Murrell DF. “Interventions for pemphigus vulgaris and pemphigus foliaceus”. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006263. DOI: 10.1002/14651858.CD006263.pub2

  29. Murrell DF., Dick S., Ahmed AR., Amagai M., Barnadas MA., Borradori L., et al. “Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus”. J Am Acad Dermatol 2008; 58(6): 1043-1046.

  30. Robinson ND, Hashimoto T, Amagai M, Chan LS. “The new pemphigus variants”. J Am Acad Dermatol 1999; 40(5 Pt 1):649-671; quiz 672-673.

  31. Joly P. “Autoimmune bullous skin diseases”. Rev Med Interne 1999; 20(1): 26-38.

  32. Anhalt GJ., Labib RS., Voorhees JJ., Beals TF., Diaz LA. “Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease”. N Engl J Med 1982; 306(20): 1189-1196.

  33. Metry DW, Hebert AA, Jordon RE. “Nonendemic pemphigus foliaceus in children”. J Am Acad Dermatol 2002; 46(3): 419-422.

  34. Anhalt GJ. “Making sense of antigens and antibodies in pemphigus”. J Am Acad Dermatol 1999; 40(5): 763-766.

  35. Stanley JR. “Pemphigus”. En: Freedberg IM, Eisen AZ, Wolff K, et al., Fitzpatrick’s dermatology in general medicine, vol. 1, 5a ed., McGraw- Hill, Nueva York, 1999, 654-666.

  36. Seishima M, Iwasaki-Bessho Y, Itoh Y, Nozawa Y, Amagai M, Ki - tajima Y. “Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in pemphigus IgG-induced signal transduction”. Arch Dermatol Res 1999; 291(11): 606-613.

  37. Lin M. S., Mascaro J M., Liu Z. “The desmosome and hemidesmo - some in cutaneous autoimmunity”. Clin Exp Immunol 1997; 107(Suppl1): 9-15.

  38. Sullivan TP, Elgart GW, Kirsner RS. “Pemphigus and smoking”. Int J Dermatol 2002; 41: 528-530.




2020     |     www.medigraphic.com